Nirvikar Dahiya MD, Abstract Co-Author: Nothing to Disclose

Christine O. Menias MD, Presenter: Nothing to Disclose

Mariam Moshiri MD, Abstract Co-Author: Consultant, Reed Elsevier Author, Reed Elsevier

Maitray D. Patel MD, Abstract Co-Author: Nothing to Disclose

Akram Mohamed Shaaban MBBCh, Abstract Co-Author: Contributor, Amirsys, Inc

Cary Lynn Siegel MD, Abstract Co-Author: Nothing to Disclose

Purpose/Aim: - To familiarize radiologists with different imaging manifestations of Tamoxifen induced changes in the uterus of women who are being treated for breast cancer  - To review indications, post treatment changes, complications, management implications, and role of the radiologist in such patients  - To discuss various imaging options for follow-up, and implications of each for management  

 Content organization: - Introduction role and use of tamoxifen therapy - Discuss the potential changes of tamoxifen therapy to the endometrium and uterus o Endometrial hyperplasia o Endometrial polyps o Endometrial cystic change o Endometrial carcinoma o Coexisting Leiomyomas, adenomyosis - Discuss imaging modalities and features of tamoxifen therapy o Transvaginal ultrasound and sonohysterogram o Role of MRI o Hysteroscopic correlation - Summary and Conclusion Summary: The purpose of this exhibit is to review the spectrum of uterine and endometrial findings at transvaginal US, hysterosonography , CT and MRI in women with breast cancer undergoing tamoxifen therapy. Various pathologic conditions produced within the uterus by this therapy will be discussed and illustrated. Potential pitfalls and mimics will also be reviewed.  

http://abstract.rsna.org/uploads/2014/14002636/14002636_5d29.pdf

Dahiya, N, Menias, C, Moshiri, M, Patel, M, Shaaban, A, Siegel, C, Imaging Features of Tamoxifen Therapy on the  Endometrium and Uterus.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14002636.html